CMV Reactivation Is Rare in the Era of Biologic Therapies for Inflammatory Bowel Disease

被引：0
|
作者：
Hissong, Erika [1 ]
Yantiss, Rhonda [1 ]
机构：
[1] Weill Cornell Med Coll, New York, NY USA
来源：
LABORATORY INVESTIGATION | 2018年 / 98卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
747
引用
收藏
页码：269 / 269
页数：1
相关论文
共 50 条
  • [31] Surgical Outcomes in Inflammatory Bowel Disease Patients and the Potential Impact of Biologic Therapies
    Cima, Robert R.
    SEMINARS IN COLON AND RECTAL SURGERY, 2012, 23 (02) : 89 - 93
  • [32] Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease
    Antonio Di Sabatino
    Lucio Liberato
    Monia Marchetti
    Paolo Biancheri
    Gino R. Corazza
    Internal and Emergency Medicine, 2011, 6
  • [33] Pharmacoeconomics and quality of life of current and emerging biologic therapies for inflammatory bowel disease
    Zisman T.L.
    Cohen R.D.
    Current Treatment Options in Gastroenterology, 2007, 10 (3) : 185 - 194
  • [34] The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease
    Holleran, Grainne
    Lopetuso, Loris
    Petito, Valentina
    Graziani, Cristina
    Ianiro, Gianluca
    McNamara, Deirdre
    Gasbarrini, Antonio
    Scaldaferri, Franco
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2017, 18 (10)
  • [35] Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease
    Cohn, H. Matthew
    Dave, Maneesh
    Loftus, Edward V., Jr.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (08) : 301 - 315
  • [36] Advances in Therapeutic Drug Monitoring in Biologic Therapies for Pediatric Inflammatory Bowel Disease
    Kapoor, Akshay
    Crowley, Eileen
    FRONTIERS IN PEDIATRICS, 2021, 9
  • [37] Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease
    Di Sabatino, Antonio
    Liberato, Lucio
    Marchetti, Monia
    Biancheri, Paolo
    Corazza, Gino R.
    INTERNAL AND EMERGENCY MEDICINE, 2011, 6 : 17 - 27
  • [38] RISK FACTORS FOR NON-ADHERENCE TO BIOLOGIC THERAPIES IN INFLAMMATORY BOWEL DISEASE
    Wentworth, Brian J.
    Buerlein, Ross C. D.
    Nakamura, Takahiro
    Tuskey, Anne G.
    Overby, M. Ashely
    Smolkin, Mark E.
    Behm, Brian W.
    GASTROENTEROLOGY, 2018, 154 (01) : S84 - S84
  • [39] Combining Therapies in Inflammatory Bowel Disease: End of the Line or a New Era?
    Judge, Ciaran
    Saeidi, Reza
    Sugrue, Kathleen
    Rabbitt, Louise
    Keogh, Aine
    Byron, Clodagh
    Zulquernain, Syed Akbar
    Gleeson, Sarah
    O'Toole, Aoibhlinn
    Buckley, Martin
    Slattery, Eoin
    Doherty, Glen
    McCarthy, Jane
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (06) : 956 - 959
  • [40] Epidemiology of Inflammatory Bowel Disease across the Ages in the Era of Advanced Therapies
    Caron, Benedicte
    Honap, Sailish
    Peyrin-Biroulet, Laurent
    JOURNAL OF CROHNS & COLITIS, 2024, 18 : ii3 - ii15
12345